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Despite the proven benefits of using antiplatelet therapy in patients undergoing percutaneous coronary
intervention (PCI), a number of key questions remain to be answered. In recent years, clopidogrel dosing
strategies among such patients have evolved considerably, with newer approaches involving loading doses
prior to PCI and increases in the time interval and loading dosage in an effort to overcome variable
responsiveness/hyporesponsiveness to platelet inhibition. Further, the role of glycoprotein (GP) IIb/IIIa
antagonists in elective stenting continues to be defined, with recent evidence suggesting that most
appropriate use of these agents is in high-risk patients with elevated troponin levels. There appears to be a
relationship between the use of GP IIb/IIIa antagonists with clopidogrel loading and attenuation of early
inflammatory and cardiac marker release. Strategies to minimize the chance of late stent thrombosis in
patients who receive drug-eluting stents (DES) are also under intense investigation. Among some patients
receiving sirolimus and paclitaxel DES, current standard long-term antiplatelet strategies may be insufficient.
Patient nonadherence to treatment and premature discontinuation and underutilization of antiplatelet
therapies by physicians remain important clinical problems with potentially dire consequences.
Key words: catheterization/diagnostic interventional<cardiac, platelets, thrombosis/hypercoagulable states,
acute coronary syndromes<ischemic heart disease, myocardial infarction<ischemic heart disease
Introduction
Platelet inhibition is an important part of standard medi-
cal management to prevent further thrombotic events and
improves outcomes in patients with acute coronary syn-
dromes (ACS) or in those who are undergoing percutaneous
coronary intervention (PCI). Important considerations con-
cerning the use of these compounds in patients undergoing
PCI currently include interindividual variability in response
to platelet inhibitors, optimal loading and maintenance
doses, preprocedure timing of antiplatelet therapy, the role
of glycoprotein (GP) IIb/IIIa antagonists in elective stenting,
strategies to minimize the chance of late stent thrombosis
in patients who receive drug-eluting stents (DES), and pre-
mature discontinuation/underutilization of post-PCI dual
antiplatelet therapy. In this article, these topics and the
recent investigations surrounding them are reviewed.
Optimizing Clopidogrel Dosing
Variability in response to clopidogrel: In managing patients
with ACS who undergo PCI, rapid and predictable platelet
inhibition for all patients is an important therapeutic goal.
Determining the optimal dose of antiplatelet therapy to
achieve this goal has been hampered by considerable inter-
patient variability in response to clopidogrel. In an initial
study designed to examine the uniformity of platelet inhi-
bition by a clopidogrel 300 mg loading dose followed by a
75 mg/day maintenance dose in patients undergoing stent-
ing, platelet function was measured by aggregation and the
expression of activation-dependent receptor expression.1 A
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normal distribution of response was demonstrated for both
measurements. Using a cutpoint of <10% absolute change
in aggregation for resistance, the prevalence of resistance
was about 50%–60% at 2 h; about 30% at 1 and 5 days; and
15%–21% at 30 days after stenting. This study highlighted
the significant prevalence of resistance and the importance
of the time when platelet studies are conducted in relation
to the time of stenting when the load was administered in
these patients. In another study involving a heterogeneous
population of 544 patients and healthy volunteers evaluated
in a post hoc analysis, platelet response to clopidogrel was
also found to follow a normal distribution; the mean change
in platelet aggregation was 41.9% (SD 20.8%) from baseline
after clopidogrel was initiated.2 In that study, hypo- and
hyper-responsiveness were defined as two standard devia-
tions below or above the mean, respectively; 4.2% of patients
were hypo-responsive and 4.8% were hyper-responsive by
these definitions. In contrast to the prior study, this inves-
tigation suggests that a smaller but significant proportion
of patients receive inadequate protection from thrombotic
adverse events despite treatment with antiplatelet therapy.
The results may have been affected by the heterogeneity
of the population and the lack of prespecified times when
platelet function was measured. Therefore, there remains a
need for platelet function tests that can consistently measure
platelet inhibition, and correlate those findings to adverse
clinical outcomes.2
Modification of clopidogrel loading doses: Antiplatelet
treatment failure due to variability in response to platelet
inhibition and delayed onset of antiplatelet effect remains
problematic. A number of trials have been conducted in
an attempt to establish the most optimal loading dose
and timing of clopidogrel administration prior to PCI. The
Clopidogrel for the Reduction of Events During Observation
(CREDO) randomized trial was the first to establish the
benefit of a longer time interval between loading dose
administration and PCI.3 However, adverse thrombotic
events continued to occur despite the use of the standard
300 mg loading dose of clopidogrel. One obvious method
proposed to achieve higher platelet inhibition is to increase
preprocedure loading doses. Indeed, the findings from
the aforementioned landmark second antiplatelet therapy
for reduction of myocardial damage during angioplasty
(ARMYDA-2) study were the basis for the change in practice
pattern currently being observed from a 300 mg loading dose
to a 600 mg loading dose of clopidogrel.4
Another recent trial evaluated 2 clopidogrel loading doses
greater than 300 mg. The Assessment of the best Loading
dose of clopidogrel to Blunt platelet activation, Inflamma-
tion, and Ongoing Necrosis (ALBION) trial was a random-
ized, multicenter, parallel-group study that compared a 300
mg loading dose of clopidogrel with two higher doses (600
and 900 mg) in 103 patients with non-ST-segment eleva-
tion (NSTE) ACS.5 Patients were randomized to the three
clopidogrel loading doses, followed by 75 mg/day of main-
tenance clopidogrel, which was administered in addition to
other standard therapy (including aspirin [ASA] therapy and
low molecular weight heparin). The higher loading doses
of clopidogrel were associated with significantly greater
inhibition to adenosine diphosphate (ADP)-induced platelet
aggregation; dose-effect relationships were observed for
onset of action (within the first 6 h at 3 time points: p<0.05
for 600 and 900 mg versus 300 mg), maximal inhibition of
platelet aggregation, 24-h areas under the curve for inhibi-
tion of platelet activation (IPA), and rates of low IPA (<10%
at 6 h) (Figure 1).5 This trial was significant because it
evaluated multiple time points during the first 24 h after
clopidogrel loading dosing and demonstrated the ability of a
900 mg clopidogrel loading dose to provide greater platelet
inhibition within 1 h and for at least 24 h. Bleeding rates were
similar in the 3 groups. Future trials will be needed to deter-
mine whether these pharmacodynamic findings translate to
improvements in clinical endpoints.
Use of a 150 mg clopidogrel maintenance dose: Ano-
ther possible method to achieve better platelet inhibition,
particularly in high-risk patients, is to increase the clopi-
dogrel maintenance dose. Given the significantly better
platelet inhibition demonstrated with a 600 mg loading






























Figure 1: Percentage inhibition of platelet aggregation after stimulation
with 5µmol/L adenosine diphosphate (ADP). Reproduced with permission
fromMontalescot G et al.5
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(CAD) already receiving standard 75 mg clopidogrel main-
tenance dosing,6 the impact of higher maintenance doses
on platelet inhibition was evaluated by von Beckerath and
colleagues.7 That double-blind study randomized 60 patients
taking chronic ASA therapy who had undergone PCI and
received a 600 mg loading dose to a clopidogrel maintenance
dose of 75 or 150 mg/day. At 30 days following randomiza-
tion, maximal 5µM ADP-induced platelet aggregation was
significantly reduced, albeit with a large variability in platelet
aggregation data, in patients treated with a 150 mg main-
tenance dose of clopidogrel (45.1% ±20.9%) compared with
the conventional dose (65.3% ±12.1%, p<0.001) (Figure 2).7
Similarly, significantly greater inhibition of platelet function
was observed in the 150 mg group, when platelet function
was measured with the VerifyNow P2Y12 assay (p = 0.004)
(Accumetrics, San Diego, Calif., USA).
Patients with type 2 diabetes have reduced responsive-
ness to antiplatelet agents,8–10 and may be at increased risk
because standard maintenance doses of clopidogrel may
not provide adequate protection from adverse thrombotic
events. A recently published pilot study was conducted in
patients with type 2 diabetes and CAD who were receiving
standard clopidogrel maintenance dosing.11 Angiolillo and
colleagues randomized 40 clopidogrel hyporesponders (out
of 64 type 2 diabetic patients) to 30 days of therapy with
clopidogrel 75 mg or clopidogrel 150 mg. The degree of
platelet inhibition was assessed at baseline, 30 days, and 30
days after resuming clopidogrel 75 mg dosing. At 30 days,
a significant reduction in maximal ADP-induced platelet
aggregation was observed in the 150 mg group compared
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Figure 2: Maximal aggregation induced by 5µm ADP in patients treated
with 2 different clopidogrel daily maintenance doses (150 and 75 mg).
Individual data are shown, along with mean (black lines) and SD (thin
lines). Reproduced with permission from von Beckerath N et al.7
baseline values was observed in the 150 mg group at 30
days following reestablishment of 75 mg clopidogrel main-
tenance dosing, confirming the transient nature that the
pharmacodynamic effect of high clopidogrel dosing confers
and the persistency of high-platelet reactivity in this high-
risk group. Notably, despite the doubling of clopidogrel
dose in the 150 mg group, more than half of those patients
still demonstrated suboptimal clopidogrel response, further
demonstrating the effect that diabetes may have on platelet
reactivity and aggregation.
A potential drawback to pushing maintenance doses of
clopidogrel to 150 mg is the potential for increases in bleed-
ing complications. However, in the recent Clopidogrel for
High Atherothrombotic Risk and Ischemic Stabilization,
Management, and Avoidance (CHARISMA) trial, safety
analyses suggested that symptomatic patients (those with
documented cardiovascular disease [CVD]) were at lower
risk for severe bleeding with combined clopidogrel and ASA
therapy than asymptomatic patients at high atherothrom-
botic risk. In CHARISMA, severe bleeding occurred in 2.0%
of asymptomatic patients treated with combined clopidogrel
and ASA; the corresponding rate of severe bleeding among
symptomatic patients was 1.6%. While certainly not proven,
the authors postulate that established CVD may be a ‘‘crude
proxy’’ for hyperactive platelets, meaning that these patients
may have a lower risk for bleeding from dual antiplatelet
administration.12 Given that the target group for higher
maintenance dosing with clopidogrel would likely be such
higher-risk patients, the risk for bleeding complications may
ultimately be deemed acceptable in this group of patients.
However, this remains entirely speculative at the present
time and requires future confirmation.
Ongoing investigation of higher maintenance dosing
with clopidogrel loading doses: Higher maintenance doses
of clopidogrel are also being evaluated in the ongoing
Clopidogrel Optimal Loading Dose Usage to Reduce Recur-
rent Events/Optimal Antiplatelet Strategy for Interventions
(CURRENT/OASIS) 7 clinical trial which will be powered
to detect clinical events.13 The CURRENT/OASIS 7 is a
clinical-end point trial with a composite primary outcome
measure of first occurrence of cardiovascular death, myocar-
dial infarction (MI), or stroke within 30 days; the co-primary
outcome is a 30-day occurrence of cardiovascular death, MI,
stroke, or recurrent ischemia. Patients with ACS undergo-
ing an early invasive strategy with intent for PCI are being
randomized to two different clopidogrel regimens: (1) 600
mg loading dose, followed by 150 mg/day for a week and
then 75 mg/day thereafter; and (2) 300 mg loading dose,
followed by 75 mg/day maintenance therapy. Additionally,
patients will be randomized to receive high ( 300 mg)
versus low-dose ( 100 mg) ASA. This prospective inter-
national trial has a planned enrollment of 14,000 patients
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Figure 3: The Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study shows that
maximal ADP-induced platelet aggregation was significantly reduced in a group of diabetic patients
who had suboptimal response to clopidogrel given a higher dose (150 mg/day) of the drug. Maximal
platelet aggregation after stimulus with 20µmol/L ADP assessed at study time points 1 (T1: baseline), 2
(T2: 30 days after randomization to either 150 or 75 mg/day), and 3 (T3: 30 days after resuming the
standard dose of 75 mg/day). Values are expressed as percentage (%) of maximum platelet
aggregation Boxes represent individual measurements; bars denote means ± SD. Reproduced with
permission from Angiolillo DJ et al.11
with unstable angina (UA) or non-ST-segment elevation MI
(NSTEMI) treated with an early invasive strategy.
Timing of Clopidogrel Therapy
Administration of clopidogrel prior to PCI has been shown
to improve post-PCI outcomes, and is widely accepted in
clinical practice. The aforementioned CREDO trial3 was the
basis for which 6 h of pretreatment was proposed to provide
the full clinical benefit of clopidogrel loading dosing. More
recently, another analysis of the CREDO population was
conducted in the 1,815 patients (1,762 analyzable) who
underwent PCI shortly after enrollment to identify the
optimal duration of treatment with a 300 mg clopidogrel
loading dose.14 Again, a longer duration of clopidogrel
pretreatment was related to a reduction in the occurrence of
the combined primary endpoint (death, MI, or target vessel
revascularization). However, 10–12 h of pretreatment was
necessary before a difference occurred between placebo
and treatment groups; and the difference between the 2
groups did not achieve statistical significance until after
15 h of pretreatment. Patients who began clopidogrel at
least 15 h before PCI had a 58.8% reduction in the relative
risk of the composite end point compared with placebo
patients (p = 0.028); whereas the occurrence of the primary
endpoint was similar in patients who received placebo and
clopidogrel initiated less than 15 h prior to PCI (Figure 4).14
These results suggest that patients receiving a 300 mg
clopidogrel dose approximately 12 h or less prior to the
procedure are not adequately protected from PCI-related
thrombotic events. Moreover, identical 28-day event rates
were found in patients receiving clopidogrel up to 10 h prior
to PCI, regardless of whether a 300
mg or 75 mg dose of clopidogrel
was administered. Accordingly, these
results suggest that if a 300 mg load-
ing dose is to be used prior to PCI,
it should be initiated at least 15–24 h
prior to the procedure. If this duration
of pretreatment is not realistic, Intra-
coronary Stenting and Antithrombotic
Regimen-Rapid Early Action for Coro-
nary Treatment (ISAR-REACT) trial
results support the use of 600 mg of
clopidogrel at least 2 h before PCI.
In fact, ISAR-REACT demonstrated
no further clinical benefit with clopi-
dogrel pretreatment with this dose
beyond 2–3 h prior to PCI.15
Elective Stenting: Combining
Glycoprotein IIb/IIIa Antagonists with
Clopidogrel
The AHA/ACC guidelines for management of UA/NS-
TEMI recommend a GP IIb/IIIa antagonist for high-risk
patients undergoing planned PCI.16 A number of studies
have focused on how adding a GP IIb/IIIa antagonist
to clopidogrel pretreatment would affect inflammation
and cardiac marker release in the setting of elective
stenting. The Clopidogrel Loading with Eptifibatide to
Arrest the Reactivity of Platelets (CLEAR PLATELETS)
study demonstrated that, compared with clopidogrel loading
alone, administration of the GP IIb/IIIa inhibitor eptifibatide
with either a 300 or 600 mg loading dose of clopidogrel was
associated with superior platelet inhibition and decreased
cardiac marker release.17
More recently, the CLEAR PLATELETS 1b trial evaluated
the effect of combining eptifibatide with clopidogrel loading
(300 or 600 mg) versus clopidogrel loading alone on early
inflammation and cardiac marker release in 120 patients
after elective cardiac stenting.18 Compared with clopidogrel
pretreatment alone, the combination reduced the release
of CK-MB, myoglobin, and troponin-I (p = 0.03, p = 0.007,
and p = 0.07, respectively). The combination group also
demonstrated significant reductions in ADP-induced platelet
aggregation and GP IIb/IIIa expression (p  0.001). The
greatest C-reactive protein (CRP) release was demonstrated
in patients with lower platelet inhibition compared with
patients with the least CRP release (p<0.003).18 The
majority of patients with the lowest CRP release received
eptifibatide (p<0.0012).18 Accordingly, an association can be
drawn between the use of eptifibatide and a lower degree of
inflammation and myocardial necrosis in patients receiving
clopidogrel loading. Although the clinical implications of
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Figure 4: Rates of death, myocardial infarction, and urgent target vessel
revascularization. Kaplan-Meier curves of the occurrence of the composite primary
endpoint of death, myocardial infarction, and urgent target vessel revascularization.
Reproduced with permission from Steinhubl SR et al.14
the attenuation of these early cardiac and inflammatory
markers requires further study, these findings suggest that
early potent platelet inhibition protects against myonecrosis
and inflammation in the first 24 h following stenting.
Prevention of Late Stent Thrombosis with Drug-Eluting Stent
Placement
The optimal duration of clopidogrel treatment following
stent placement is unknown. Late thrombotic events have
been reported to occur among patients who receive DES,
and challenge whether current recommended postprocedu-
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Figure 5: Incidence of late thrombosis occurring more than a year poststent
placement. Adapted with permission from Bavry AA et al.19
A meta-analysis of 14 randomized clinical trials
involving 6,675 patients who received sirolimus
and paclitaxel DES or bare metal stents (BMS)
suggested that there may not be a safe interval after
which clopidogrel may be discontinued.19 In that
analysis, 8 trials had more than 12 months of follow
up. The incidence of late thrombosis occurring >1
year per 1,000 patients after the index procedure
was substantially higher in DES patients compared
with patients who received BMS (Figure 5).19
An observational analysis from the BAsel stent
Kosten Effektivitäts Trial-LAte Thrombotic Events
(BASKET-LATE) trial identified 746 patients who
were without major adverse events 6 months after
DES or BMS placement, and had discontinued
clopidogrel. Although there were no differences in
cumulative rates of death or MI between patients
who received DES (versus BMS), higher rates
of death and MI were observed after clopidogrel
discontinuation in patients receiving DES (versus
BMS; 4.9% versus 1.3%, respectively) at 18-month
follow-up.20 Additionally, a recently reported observational
study in 4,666 patients who were event-free at 6- and
12-month follow-ups showed that clopidogrel use was a
significant predictor of lower adjusted rates of death (2%
versus 5.3%; p = 0.03, and 0% versus 3.5%, p = 0.004,
respectively) and death or MI (3.1% versus 7.2%; p = 0.02,
and 0% versus 4.5%, p<0.001, respectively) among patients
with DES at 24 months; whereas patients who received
BMS demonstrated no differences in these outcomes at 12-
and 24-month follow-up. These data suggest that extended
clopidogrel therapy can reduce the incidence of late
thrombotic events in patients who have DES placement.21
However, since this has not been studied in the
setting of a large randomized clinical trial, the extent
to which the duration of clopidogrel therapy should
be extended remains unknown.
Underuse of Antiplatelet Strategies Postpercutaneous
Coronary Intervention: The Problem of Premature
Discontinuation
Undertreatment of outpatients with atherothrom-
bosis has been problematic, as was highlighted
in a recent review of data from an international
atherothrombosis registry in which widespread
underutilization of proven therapies for manage-
ment of cardiovascular risk factors was identified.22
In that review of 67,888 patients in 44 countries
with CAD, cerebrovascular disease, peripheral arte-
rial disease, or  3 risk factors for atherothrombo-
sis, there was a 78.6% overall utilization rate for
antiplatelet agents; rates of use ranged from 53.9%
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for patients with  3 risk factors to 85.6% for patients with
CAD.
Dual antiplatelet therapy with ASA and clopidogrel is
currently recommended following PCI as follows:23
• In appropriate patients, ASA 325 mg/day is recom-
mended for at least 1 month after BMS placement,
3 months after sirolimus-eluting stent placement, 6
months after paclitaxel-eluting stent placement; sub-
sequently ASA 75 to 162 mg should be continued
indefinitely.
• Clopidogrel 75 mg/day is recommended for at least
1 month after BMS placement (at least 2 weeks in
patients at increased risk for bleeding), 3 months after
sirolimus-eluting stent placement and 6 months after
paclitaxel-eluting stent placement; however, it should
ideally be continued up to 12 months in patients who
are not at high risk for bleeding.
Given the recent findings of late stent thrombosis even
with the use of guideline-recommended post-PCI dual
antiplatelet therapy, early discontinuation of this important
post-PCI adjunctive strategy by patients or health care
providers is especially troubling. A study conducted by
Eisenstein and colleagues suggests that the extension of
clopidogrel use reduces late thrombotic events with DES
placement; and premature discontinuation of antiplatelet
therapy is associated with increased risk for early (subacute)
stent thrombosis and late (>30 days) stent thrombosis.21
Premature discontinuation of antiplatelet therapy was found
to be an independent predictor of subacute (hazard ratio
[HR], 161.17), late (HR, 57.13), and cumulative (HR, 89.78)
stent thrombosis in 49 patients with stent thrombosis
after successful sirolimus or paclitaxel DES placement.24
Median follow-up of 19.4 months in 1,911 patients who
received DES identified a 3.3% incidence of stent thrombosis
in patients who had completely discontinued antiplatelet
therapy (versus 0.6% in those who had not discontinued
therapy; p = 0.004), and a 7.8% incidence in patients who
had prematurely discontinued ASA or clopidogrel, or both
platelet inhibitors (versus. 0.5% in those who had not
prematurely discontinued therapy; p<0.001).25
In another study, antiplatelet therapy had been discontin-
ued after the procedure in 57% of the patients who developed
stent thrombosis (versus 1.7% of patients who did not
develop stent thrombosis [p<0.001]) in 652 patients who
received sirolimus DES.26 Moreover, a 9-fold higher likeli-
hood of mortality over 11 months has been observed to occur
in patients with acute MI treated with DES who discontinued
thienopyridine therapy early, by 30 days (versus those who
had not stopped their therapy early [p<0.0001]).27 Given
these statistics, it is especially unfortunate that premature
discontinuation has been found to occur in an unacceptably
high proportion (29%) of patients who undergo DES stent
placement.24
TABLE 1: Recommendations to eliminate the chance for premature discontinuation of thienopyridine therapy. Adapted with permission from Grines CL
et al.28
• Strong consideration of drug-eluting stent avoidance in patients
not expected to comply with 1 year of therapy
• Educate healthcare providers who perform invasive or surgical
procedures concerning the potential catastrophic risks of
premature discontinuation of thienopyridine therapy. These
professionals should be instructed to contact the patient’s
cardiologist if issues concerning any patient’s antiplatelet
therapy are unclear
• Consider use of BMS or performance of balloon angioplasty
with provisional stent implantation in patients likely to require
invasive or surgical procedures within 1 year
• Defer elective procedures with significant risk of perioperative
or postoperative bleeding until appropriate recommended
duration of thienopyridine therapy is completed (12 months
following Drug-eluting stent placement if not at high risk for
bleeding and a minimum of 1 month for bare metal stent
placement)
• Greater effort required by health care professionals concerning
discharge education about the rationale for thienopyridine
therapy and the significant risks of premature discontinuation
of therapy
• If thienopyridine therapy must be discontinued in patients
treated with DES, aspirin should be continued (if possible)
and the thienopyridine restarted as soon as possible
postprocedure
• Specific instruction to contact treating cardiologist before
stopping antiplatelet therapy, even if instructed to do so by
another health care provider
• Health care industry, insurers, the US Congress, and the
pharmaceutical industry should ensure issues such as drug
cost do not cause patients to prematurely discontinue
thienopyridine therapy
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A number of patient-related factors may cause inappro-
priate early discontinuation of dual antiplatelet therapy
including: cost, lack of patient education concerning the
importance of these therapies, older age, lack of formal
education, inadequate discharge instructions, and lack of
referral for cardiac rehabilitation. However, health care
providers may also place patients at risk for late stent throm-
bosis by interrupting antiplatelet therapies prior to invasive
or surgical procedures. Even though it is usually safe for
patients to continue their antiplatelet therapy during minor
routine procedures such as dental cleanings and extractions,
physicians and dentists may nevertheless broadly instruct
their patients that ‘‘blood thinners should be stopped’’ with-
out distinguishing between warfarin and platelet inhibitors
or considering the critical rationale for dual platelet inhi-
bition in this patient subset.28 Indeed, it is especially
important to promulgate practices that reduce the chance
for premature discontinuation of clopidogrel. A number of
recommendations were recently published in a science advi-
sory by Grines and colleagues with the goal of eliminating
premature discontinuation of thienopyridine therapy, and
these are summarized (Table 1).28 Notably, although this
recent publication recommends dual antiplatelet therapy for
12 months post-DES placement, the fact that the optimal
duration of therapy in this setting has not been determined
remains an important clinical consideration.29
Conclusion
A number of important topics continue to dominate the
literature concerning the contemporary use of antiplatelet
therapies in patients undergoing PCI. Clopidogrel dosing
strategies have evolved in recent years—first with the
introduction of the standard practice of loading doses
prior to PCI, and more recently by increasing the time
interval and loading dosage of clopidogrel in an attempt
to overcome variable responsiveness/hyporesponsiveness
to platelet inhibition. The role of GP IIb/IIIa antagonists
in this setting continues to be clarified, but it currently
appears that their most appropriate use is in high-risk
patients with elevated troponin levels; recent findings
suggest an association between the use of GP IIb/IIIa
antagonists with clopidogrel loading and attenuation of
early inflammatory and cardiac marker release. Another
critical consideration concerns DES placement and an
observed excess occurrence of late thrombotic events, an
issue suggesting that current standard long-term antiplatelet
strategies post-PCI may be inadequate in some patients who
receive sirolimus and paclitaxel DES; also that extension of
dual antiplatelet therapy and measures to prevent its early
discontinuation following PCI are necessary. Premature
discontinuation of recommended thienopyridine therapy
in patients treated with coronary artery stents remains
an important clinical problem with potentially catastrophic
risks.
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